Related Experiment Video
Updated: Nov 25, 2025
07:35
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
Published on: October 11, 2018
7.8K
Multiplicity for a group sequential trial with biomarker subpopulations.
Ting-Yu Chen1, Jing Zhao2, Linda Sun2
1The University of Texas Health Science Center at Houston, TX, USA.
Contemporary Clinical Trials
|December 18, 2020
Summary
New statistical methods improve drug development by analyzing biomarker subpopulations in clinical trials. These group sequential designs enhance trial power and optimize patient selection for targeted therapies.
Area of Science:
- Biostatistics
- Clinical Trial Design
- Pharmacogenomics
Background:
- Biomarker subpopulations are crucial for targeted therapy drug development.
- Biomarkers enhance patient selection, improving treatment outcomes and trial efficiency.
- Current methods may not fully account for correlations within nested subgroup analyses.
Purpose of the Study:
- To introduce novel group sequential designs for analyzing nested biomarker subpopulations.
- To ensure full control of the family-wise Type I error rate in these designs.
- To improve statistical efficiency compared to traditional methods like Bonferroni correction.
Main Methods:
- Development of group sequential designs incorporating the complete correlation structure of nested subgroups.
- Application of these methods to simultaneous analysis of broad and targeted populations.
- Evaluation of family-wise Type I error rate control.
Main Results:
- The proposed designs offer enhanced statistical power or reduced sample size compared to Bonferroni methods.
- These methods effectively manage Type I error rates while analyzing complex subgroup structures.
- Improved efficiency in identifying effective patient populations for targeted therapies.
Conclusions:
- Novel group sequential designs provide a more efficient framework for biomarker-driven drug development.
- These methods support robust decision-making in targeted therapy trials by optimizing subgroup analysis.
- The approach facilitates inclusive regulatory labeling by accurately defining treatment efficacy across populations.
Related Concept Videos
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
86
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
86
01:20Comparing the Survival Analysis of Two or More Groups
412
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
412
01:12Analysis of Population Pharmacokinetic Data
556
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
556
01:15Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs
74
Body:Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
74
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
69
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
69
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
63
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
63